VCN Enhancer Composition for Efficient HSPC Lentiviral Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in efficiently transducing hematopoietic stem and progenitor cells, leading to low transduction efficiency, high vector copy numbers, and increased costs due to the need for large amounts of viral vectors.
Innovation Solution
Development of lentiviral vectors that transduce hematopoietic stem and progenitor cells with improved efficiency, achieving at least 50% transduction and an average vector copy number of 0.5 to 5, with viability rates of at least 75% and endotoxin levels below 5 EU/mL, using CD34+ and CD133+ cells at a multiplicity of infection (MOI) of 10 to 30.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy methods are used to transduce hematopoietic stem and progenitor cells, then transduction efficiency is low, but increasing viral vector dosage to improve transduction efficiency increases costs and potential harmful effects
Solution Approach 1:
The patent modifies physical-chemical parameters of the transduction process by using ionizing radiation to induce chromatin relaxation and increase cellular permeability. This changes the cellular state to be more receptive to viral vectors, thereby improving transduction efficiency without requiring proportionally higher vector doses. The radiation treatment alters DNA accessibility and membrane properties, creating favorable conditions for efficient gene delivery at moderate vector concentrations.
Solution Approach 2:
The patent applies preliminary ionizing radiation treatment to hematopoietic stem and progenitor cells before introducing the viral vector. This pre-treatment modifies the cellular state to enhance subsequent transduction efficiency. By preparing the cells in advance through radiation-induced chromatin relaxation and membrane permeability changes, the system achieves better transduction outcomes with reduced vector requirements.
2Reliability
If high multiplicity of infection (MOI) is used to improve transduction efficiency, then more viral vectors are required, but this increases costs and potential toxicity
Solution Approach 1:
The patent changes the cellular reception parameters through ionizing radiation treatment, making cells more susceptible to viral transduction at lower MOI values. The radiation-induced modifications to chromatin structure and membrane properties allow efficient gene uptake without requiring high vector concentrations that would increase toxicity and cost.
Solution Approach 2:
Ionizing radiation acts as an intermediary that mediates between the viral vector and the target cells. It creates a permissive cellular state that facilitates viral entry and gene expression without requiring direct high-dose vector application. This intermediary treatment reduces the need for high MOI by preparing the cellular environment to be more receptive to the therapeutic payload.
3Reliability
If conventional transduction methods are used, then vector copy number per cell is low, but achieving therapeutic levels requires large amounts of viral vectors increasing clinical trial costs
Solution Approach 1:
The patent employs ionizing radiation to fundamentally change cellular parameters including chromatin accessibility and nuclear envelope permeability. These parameter changes enable higher vector copy numbers per cell at lower overall vector dosages. The radiation treatment creates a cellular environment where each vector molecule is more likely to successfully integrate and persist, improving the copy number efficiency without requiring proportionally higher doses.
Data Source
AI summary
The invention provides improved gene therapy methods and compositions.